On January 8th, according to the official WeChat account of Geely Technology, DaKeWei& Reg; Enqutabine Propenofovir Tablets (II), Enqutabine 200mg/Propenofovir 25mg, F/TAF) have been approved by the National Medical Products Administration (NMPA) for pre exposure prophylaxis (PrEP) for adults and adolescents at least 35kg in weight at risk of human immunodeficiency virus type 1 (HIV-1) infection, to reduce the risk of HIV-1 infection due to high-risk sexual behavior. Previously, Gilead Entratabine Propenofovir Tablets had been approved in China for use in combination with other antiretroviral drugs in the treatment of HIV-1 infections in adults and adolescents (aged 12 years and above and weighing at least 35kg).
Pre exposure prevention refers to the use of specific antiviral drugs by individuals who have not yet been infected with HIV before engaging in behaviors that are susceptible to HIV infection, in order to prevent HIV infection. It is an important biomedical measure for HIV prevention. In August 2020, Gilead Scientific Enqutabine Tenofovir tablets were approved, becoming the first drug in China approved for pre exposure prevention of HIV in uninfected populations.
At present, sexual transmission has become the main route of HIV transmission in China. More than 95% of newly diagnosed HIV infected individuals in our country are infected through sexual means, and unsafe sexual behavior is the main cause of HIV sexual transmission. Unsafe sexual behaviors with a high risk of HIV infection include unprotected male same-sex sex, non fixed sexual partners, and paid sex.